RaySight MedTech Participates in the Inaugural Conference of the Cardiovascular Branch of the National Health Industry Enterprise Management Association, Showcasing Its Integrated AI-Driven Cardiovascular Intervention Platform

On December 19-20, 2025, the "Inaugural Conference of the Cardiovascular Branch of the National Health Industry Enterprise Management Association and the Intelligent Empowerment·AI-enabled Innovation Exchange Conference for Interventional Diagnosis and Treatment" was successfully held in Beijing. Zheng Lingxiao, founder and CEO of RaysightMed, was elected as the vice president of the branch, and Ma Jun, co-founder and CTO, was elected as a standing committee member.

RaysightMed Founder and CEO Lingxiao Zheng Attends the Inaugural Meeting of the Cardiovascular Medicine Branch (Leftmost)

RaysightMed Founder and CEO Lingxiao Zheng Attends the Certificate Issuance Ceremony for the Deputy Director of the Branch (Rightmost)

RaysightMed Co-Founder and CTO Ma Jun Attends the Certificate Awarding Ceremony for Standing Committee Members (Fourth from the Right)

This conference brought together clinical experts, research scholars, healthcare institution managers, and industry representatives in the cardiovascular field to jointly witness the establishment of the Cardiovascular Medicine Branch. The branch, initiated by Professor Liu Jian from Peking University People's Hospital, aims to build a "production-research-application" collaborative platform to promote the deep integration of academic research, technological innovation, and industrial application in the cardiovascular field, as well as to support industry standardization and service level improvement.

Introduction to the Integrated Platform for Precision Cardiovascular Interventional Diagnosis and Treatment

On December 20, during the thematic sharing session, Ma Jun, co-founder and CTO of RaysightMed, gave a presentation titled "AI + Robotics Integrated Cardiovascular Diagnosis and Treatment," systematically introducing RaysightMed's layout and practices in the entire process of precision cardiovascular interventional diagnosis and treatment.

RaysightMed Co-Founder and CTO Ma Jun Delivers Keynote Speech

Preoperative Precision Screening: RuiXin-FFR (RaysightMed-FFR)

Based on AI and three-dimensional computational fluid dynamics technology, RaysightMed's RuiXin Score can achieve non-invasive and precise coronary physiological assessment. This product, using only coronary CTA images, can simultaneously obtain anatomical and functional information.Without additional image acquisition and administration of stress medications，Accuracy, sensitivity, and specificity reached 92%, 90%, and 95%, respectively, ranking at a globally leading level.Achieving secure hospital deployment is also one of the major advantages of Raysight-FFR. The product offers multiple internal hospital deployment options and has obtained the Level 3 Information Security Certificate, fully meeting the data security control requirements of hospitals.CurrentlyRaysightMed has served over 800 hospitals across China, cumulatively assisting in the diagnosis and treatment of 200,000 patients.

Intraoperative Intelligent Diagnosis: RaysightMed AngioQFA

RaysightMed Angio QFA, based on coronary angiography images, adopts a domestically首创 circuit-like algorithm in China, generating an accurate coronary simulation model within 10 seconds. It simultaneously achieves morphological evaluation (QCA), functional evaluation (FFR), microcirculatory resistance index (IMR), and surgical planning. The FFR and IMR test results show over 95% consistency with the invasive gold standard.

Intraoperative Intelligent Treatment:Interventional Surgical Robot - Precise, Efficient, Safe

RaysightMed's cardiovascular interventional surgical robot adopts a master-slave separation design, enabling doctors to operate from a separate room and effectively avoiding radiation exposure. The system offers high-precision imaging recognition and instrument control, multi-instrument collaboration, dual-system assurance with force feedback and imaging feedback, and supports 5G remote surgery, aiding in the treatment of complex cases and the balanced allocation of medical resources.

RaysightMed has built an integrated platform for precision cardiovascular interventional diagnosis and treatment, covering preoperative diagnosis and surgical planning, intraoperative intelligent therapy, and postoperative health management.

Join Hands and Move Forward Together, Embrace the Future

As the vice president unit of the Cardiovascular Medicine Branch, RaysightMed will continue to play a bridging role, integrating clinical, scientific research, and industry resources. Driven by innovation and aiming for industrial upgrading, it will work with industry partners to push the cardiovascular field into a new stage of high-quality development.

RaysightMed CEO Zheng Lingxiao Interprets the New Paradigm of "Macro + Micro" AI Coronary Diagnosis and Treatment at Jinan University

University-Enterprise Collaboration | RaysightMed Partners with the First Affiliated Hospital of Jinan University to Jointly Cultivate Interdisciplinary Talent in Intelligent Healthcare

Comprehensive and Precise, Evidence-Based Decision Making | Zhangzhou People's Hospital Successfully Diagnoses and Treats Occult Coronary Artery Disease Using RaysightMed AngioQFA